Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

PER® estimates that this online enduring material will be designated for a maximum of 1.0 credit for nurses.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Community Practice Connections™: The Latest Advances on PI3K Inhibition in Breast Cancer: What You Need to Know

Release Date: August 30, 2019
Expiration Date: August 30, 2020
Media: Internet - based

Activity Overview

This educational activity will bring together leading clinical experts in the management of patients with breast cancer using phosphoinositide 3-kinase (PI3K) inhibitors. The in-depth program will cover best practices for identification of patients with breast cancer who are most likely to benefit from these agents, the specific mechanistic characteristics of available agents, and techniques for managing adverse events appropriately. In addition, available clinical trial data will be examined and contextualized in patient cases, including trials of emerging strategies utilizing combination approaches incorporating PI3K inhibition. The program will include a focused discussion on optimizing the use of PI3K inhibitors using the most advanced and most accurate available tumor-testing technologies.

Benefits of Participating

  • Update and confirm your knowledge of best practices in the management of patients with advanced breast cancer
  • Learn the best approaches for identification of trials of PI3K inhibitors that may be appropriate for selected patients with breast cancer
  • Through in-depth review of clinical trials in progress, learn the latest developments on PI3K inhibitors in breast cancer
  • Recognize the toxicity profile of PI3K inhibitors and how this may affect treatment decisions as an expanding array of targeted therapies and combinations becomes available in breast cancer

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward community oncologists and hematologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss that rationale supporting the role of PI3K inhibition in the treatment of patients with breast cancer
  • Review data from recent clinical trials evaluating efficacy and safety of PI3K inhibitors in breast cancer treatment
  • Examine strategies for optimizing treatment outcomes and patient selection for PI3K inhibition
  • Discuss effective strategies to proactively counsel and manage adverse events associated with PI3K inhibition in the treatment of patients with breast cancer

Faculty, Staff, and Planners’ Disclosures

Faculty

Tiffany A. Traina
Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo. Consultant: Genentech, Medivation, Pfizer, AstraZeneca, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme.

Hope Rugo
Hope Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics, MacroGenics, Immunomedics.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the companies that provided commercial support for this program.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
2930
Filter By